title: Agomelatine for the treatment of patients with fibromyalgia and depressive symptomatology: an uncontrolled, 12-week, pilot study.
abstract: BACKGROUND
  Agomelatine, a melatonin agonist and selective 5-HT2C antagonist, is a novel antidepressant with sleep-enhancing properties. The purpose of this study was to assess the efficacy and tolerability of agomelatine among patients with fibromyalgia and depression.
  
  
  METHODS
  23 patients with fibromyalgia and depressive symptomatology received 25-50 mg of agomelatine daily for 12 weeks. The primary outcome measure was the change of the Beck depression inventory score. Secondary outcome measures included the hospital anxiety and depression scale, Pittsburgh sleep quality index, Fibromyalgia Impact Questionnaire, short-form health survey, brief pain inventory and patient's global impression scale.
  
  
  RESULTS
  Agomelatine significantly improved depression, global fibromyalgia severity and pain intensity but effect sizes were small. No improvement was seen in sleep quality. Patients categorized as responders to treatment had milder disease severity than non-responders. Agomelatine therapy was well tolerated and patients only reported mild and transient side effects.
  
  
  CONCLUSIONS
  Agomelatine slightly improved depressive and fibromyalgia symptomatology but did not improve sleep quality. Our data do not support agomelatine as a first-line treatment option for the treatment of fibromyalgia and depression.
authors.affiliation: Instituto de Neurociencias, Universidad de Granada, Granada, Spain.
authors.forename: E P
authors.initials: EP
authors.lastname: Calandre
authors.affiliation: Instituto de Neurociencias, Universidad de Granada, Granada, Spain.
authors.forename: M
authors.initials: M
authors.lastname: Slim
authors.affiliation: Instituto de Neurociencias, Universidad de Granada, Granada, Spain.
authors.forename: J M
authors.initials: JM
authors.lastname: Garcia-Leiva
authors.affiliation: Instituto de Neurociencias, Universidad de Granada, Granada, Spain.
authors.forename: C M
authors.initials: CM
authors.lastname: Rodriguez-Lopez
authors.affiliation: Instituto de Neurociencias, Universidad de Granada, Granada, Spain.
authors.forename: P
authors.initials: P
authors.lastname: Torres
authors.affiliation: Instituto de Neurociencias, Universidad de Granada, Granada, Spain.
authors.forename: F
authors.initials: F
authors.lastname: Rico-Villademoros
mesh_terms: D000081:Acetamides / Q000627:therapeutic use*; D000328:Adult; D003866:Depressive Disorder / Q000150:complications / Q000188:drug therapy*; D005260:Female; D005356:Fibromyalgia / Q000150:complications / Q000188:drug therapy*; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D010865:Pilot Projects; D012702:Serotonin Antagonists / Q000627:therapeutic use*; D016896:Treatment Outcome; D009281:Naphthalenes
chemical_list: D000081:Acetamides; D012702:Serotonin Antagonists; C084711:agomelatine; D009281:Naphthalenes